Related references
Note: Only part of the references are listed.Ketamine in the Treatment of Depressive Episodes
Philipp Ritter et al.
PHARMACOPSYCHIATRY (2020)
Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3
Rachel Ochs-Ross et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2020)
The Concurrent Treatment With Intravenous Ketamine and an Irreversible Monoamine Oxidase Inhibitor for Treatment-Resistant Depression Without Hypertensive Crises
Jay Ching Chieh Wang et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2020)
Effects of subcutaneous esketamine on blood pressure and heart rate in treatment-resistant depression
Lorena Catarina Del Sant et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2020)
Safety and efficacy of esketamine nasal spray in a depressed patient who was being treated with tranylcypromine: A case report
David L Dunner et al.
NEUROLOGY PSYCHIATRY AND BRAIN RESEARCH (2020)
Ketamine and Monoamine Oxidase Inhibitor Combination Utility, Safety, Efficacy?
Hugo Bottemanne et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2020)
Efficacy and Adverse Effects of Tranylcypromine and Tricyclic Antidepressants in the Treatment of Depression A Systematic Review and Comprehensive Meta-analysis
Sven Ulrich et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2020)
Patients with major depressive disorder have lower cerebral serotonin 4 receptor binding than healthy controls
K. Koehler-Forsberg et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2020)
Global Burden of Disease and the Impact of Mental and Addictive Disorders
Juergen Rehm et al.
CURRENT PSYCHIATRY REPORTS (2019)
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study
Vanina Popova et al.
AMERICAN JOURNAL OF PSYCHIATRY (2019)
Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)
Maggie Fedgchin et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2019)
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial
Ella J. Daly et al.
JAMA PSYCHIATRY (2019)
Long-term safety of esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: SUSTAIN-2 phase 3 study
E. Wajs et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2019)
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis
Samuel T. Wilkinson et al.
AMERICAN JOURNAL OF PSYCHIATRY (2018)
Concurrent use of ketamine and monoamine oxidase inhibitors in the treatment of depression: A letter to the editor
R. B. Katz et al.
GENERAL HOSPITAL PSYCHIATRY (2018)
Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions
Patricio Riva-Posse et al.
JOURNAL OF AFFECTIVE DISORDERS (2018)
Mechanisms of ketamine action as an antidepressant
P. Zanos et al.
MOLECULAR PSYCHIATRY (2018)
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression A Randomized Clinical Trial
Ella J. Daly et al.
JAMA PSYCHIATRY (2018)
Side-effects associated with ketamine use in depression: a systematic review
Brooke Short et al.
LANCET PSYCHIATRY (2018)
Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression
C. K. Loo et al.
ACTA PSYCHIATRICA SCANDINAVICA (2016)
Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: A report of two cases
Lucie Bartova et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2015)
Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression
Le-Ben Wan et al.
JOURNAL OF CLINICAL PSYCHIATRY (2015)
MAO-Inhibitors - A Treatment Option for Treatment Resistant Depression
S. Koehler et al.
FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE (2014)
Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression
Rebecca B. Price et al.
BIOLOGICAL PSYCHIATRY (2009)
Antidepressant effects of ketamine in depressed patients
RM Berman et al.
BIOLOGICAL PSYCHIATRY (2000)
Share Paper
